The Line
The Line Podcast
The Line Podcast: Live from Taipei!
0:00
-1:40:44

The Line Podcast: Live from Taipei!

And other places.

In the latest episode of The Line Podcast, recorded on November 20th, 2026, Matt Gurney hosts a special edition of the show with three guests and three very different conversations.

This episode is brought to you by Cameco. Building Canada’s energy future means creating jobs for Canadian workers. That’s why the AP1000 reactor is the right choice for Canada: it is already operating and ready to deliver the power we need. Choosing the AP1000 means a reactor built by Canadians, creating skilled jobs in construction, fabrication and the trades while keeping more investment and economic benefits here at home. If we are serious about creating Canadian jobs and strengthening our economy, the choice is clear. To learn more, visit ap1000.cameco.com.

First up, Jen Gerson joins Matt from Taiwan, where she’s enjoying the sights, the food, and the pleasures of a good old-fashioned junket. Jen explains what a junket actually is, what she’s been seeing and learning during her visit, and why she’s fallen so hard for the local cuisine. But she also has some more serious observations about Taiwan, including why so much of what she’s seeing reminds her, in unexpected ways, of Canada.

Next, David Shipley joins Matt to discuss the recent wave of cyber crashes and disruptions. What’s going on? Is artificial intelligence playing a role? Are we seeing the early signs of something much bigger, or are people connecting dots that don’t actually belong together? Matt and David sort through what might be happening, what probably isn’t happening, and how worried we should be about the increasingly complicated technological systems on which modern life depends.

This episode is also brought to you by BioCanRx. We’ve been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This month we’re addressing common questions, like: do these therapies have export potential?

The farthest advanced BioCanRx-supported therapies are still in clinical trials here in Canada, but other countries are already expressing interest based on their efficacy and lower cost. Canadian-developed CAR-T technology from the CLIC group is already being used to treat clinical trial patients in Denmark, and other countries with high numbers of leukemia cases have expressed interest. A successful clinical trial in another country can be an important first step toward bringing that therapy to market there. If BioCanRx-supported therapies continue to be trialed outside Canada, it sends a strong signal that made-in-Canada immunotherapies will find a receptive international market.

Thanks to BioCanRx for continuing to partner with The Line to share this information. Visit BioCanRx.com to learn more.

Finally, Matt is joined by Mitch Heimpel of Texture Communications to discuss Matt’s recent column arguing that Canada’s political class is in desperate need of an emergency gonad transplant. It’s not just the politicians themselves. Their aides, advisers and staffers could use one, too. Matt and Mitch discuss what’s gone wrong with the culture of Canadian politics, why so many people seem terrified of speaking plainly or taking risks, and whether anyone in Ottawa still has the courage to stand up and say what needs to be said.

All that and more in the latest episode of The Line Podcast.

YouTube:

Video goes live at 6 p.m Eastern/4 Mountain.

Spotify:

Apple:

And plenty more options here.

Please sign up at those options not just for this episode, or future episodes of The Line Podcast, but so that you can also receive our other podcast series, On the Line, which releases new episodes every Tuesday morning. In case you missed it, here is last Tuesday’s episode, where host Matt Gurney is joined by two guests, Scott Stinson to chat the geopolitics of hockey and, um, sandwiches, and Alan Findlay about the state of Alto, our theoretical high-speed-rail program.

That’s all for now! Talk to you guys soon.


The Line is entirely reader and advertiser funded. No federal subsidies, no bailouts. If you value our work, please consider supporting us by subscribing or making a donation. Donations are not subscriptions and do not unlock paywalled content, but they help keep The Line independent


To contact The Line with a general inquiry or comment, please email info@readtheline.ca. For other ways to connect with us or to follow us on social media, please see our LinkTree.

Discussion about this episode

User's avatar

Ready for more?